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ABSTRACT 
 
A  modified  simple,  selective,  rapid,  precise  reversed  phase  high  performance  liquid 
chromatography method has been developed and validated for the simultaneous estimation of 
ketorolac and sparfloxacin. The separation was made in a Hypersil-Keystone C-18 column 
using a methanol: water (60:40, v/v) (pH 3.1) as mobile phase at 308 nm. The mobile-phase 
flow rate and the sample volume injected were 0.9 ml/min and 20 µl, respectively. Retention 
time of sparfloxacin and ketorolac was found to be 3.181 and 4.473 minutes respectively. The 
correlation coefficient of both drugs was found to be 0.999. The accuracy of ketorolac was 
found to be 99.82% - 100.55% whereas for sparfloxacin, it was 99.76% - 99.89%. Over all % 
RSD was found to be less than 2%. The method was validated according to ICH guidelines 
with  respect  to  linearity,  accuracy,  precision,  robustness,  specificity,  etc.  The  developed 
method can be used for routine analysis of ketorolac and sparfloxacin in their pharmaceutical 
dosage forms. 
1. Introduction  
Ketorolac or ketorolac trimethamine or 5-amino-1-cyclopropyl-
7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-
oxo-3-quinolinecarboxylic acid (Figure 1) is a well known non-
steroidal  anti-inflammatory  drug  (NSAID)  in  the  family  of 
heterocyclic acetic acid derivatives, often used as an analgesic. 
Sparfloxacin  (SPFX)  belongs  to  the  class  of  fluoroquinolone 
antibiotics,  used  in  the  treatment  of  bacterial  infections  that 
inhibit  the  bacterial  DNA  gyrase  or  the  topoisomerase  IV 
enzyme by inhibiting DNA replication and transcription [1-2].  
 
Since inflammation can be due to post operative conditions or 
some microbial infections, a combination of these two drugs can 
be  useful  to  treat  various  bacterial  infections  accompanied  by 
inflammations of various parts of body like dental infection, eye 
infection etc. Also in the form of eye drops, these drugs can be 
used  ato  treat  keratitis  and  conjunctivitis  [3-4].  Therefore,  for 
effective  treatment  these  drugs  are  usually  prescribed  in 
combination.  Some  HPLC  methods  have  been  developed  for 
determination of these drugs individually but no HPLC method 
for  simultaneous  estimation  of  these  two  drugs  using  C18 
column has been reported till date [5-9].   
 
In the present study, an attempt has been made to develop and 
validate a method for the simultaneous estimation of ketorolac 
and sparfloxacin, It can also be applied for routine analysis of 
either one or of any combinations of these drugs in dosage forms.
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Figure 1: Structure of Ketorolac (a) and Sparfloxacin (b)
 
2. Material & Methods 
2.1 Methods 
I. Preparation of Standard Solution 
Standard  stock  solutions  of  sparfloxacin  and  ketorolac  were 
prepared separately by dissolving 100 mg of drug in 100 ml of 
methanol to get concentration of 1000 µg/ml. From the standard 
stock solution, mixed working standard solution was prepared to 
contain 100 µg/ml of sparfloxacin and 100 µg/ml of ketorolac. 
Also working stock solution (100 µg/ml) was prepared for both 
sparfloxacin and ketorolac separately [10].   
II. Preparation of Sample Solution 
 Ketorolac  and  Sparfloxacin  eye  drops  were  purchased 
individually  from  local  market  with  label  claim  as  each  ml 
contains  4  mg  of  Ketorolac  and  3  mg  of  Sparfloxacin  in 
individual eye drops. 2.5 ml was withdrawn from ketorolac eye 
drops and diluted with mobile phase to make up the volume to 10 
ml in a volumetric flask such that it contained 1000 
ketorolac  and  3.33  ml  was  withdrawn  from  sparfloxacin  eye 
drops and diluted with mobile phase to make up the volume to 10 
ml  in  a  volumetric  flask  such  that  it  contains  1000 
sparfloxcin. Both solutions were mixed (working mixture sample 
solution) to contain 500 µg/ml concentration of Sparfloxacin and 
500  µg/ml  concentration  of  Ketorolac.  Further  dilutions  were 
made to obtain mix solution as concentration 5, 10, 50 
further use [10]. 
2.2 Method Validation [11] 
 I. Linearity and Range 
The linearity of an analytical procedure is its ability (within a 
given range) to obtain test result which are directly proportional 
to the concentration (amount) of analyte in the sample. It was 
studied by analyzing five concentrations of the drug in triplicate.
II. Precision 
Precision  of  the  system  was  evaluated  by  analyzing  six 
independent  standard  preparations  and  %  RSD  value  was 
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drops and diluted with mobile phase to make up the volume to 10 
h  that  it  contains  1000  µg/ml  of 
sparfloxcin. Both solutions were mixed (working mixture sample 
g/ml concentration of Sparfloxacin and 
g/ml  concentration  of  Ketorolac.  Further  dilutions  were 
centration 5, 10, 50 µg/ml for 
The linearity of an analytical procedure is its ability (within a 
given range) to obtain test result which are directly proportional 
mount) of analyte in the sample. It was 
studied by analyzing five concentrations of the drug in triplicate. 
Precision  of  the  system  was  evaluated  by  analyzing  six 
independent  standard  preparations  and  %  RSD  value  was 
calculated  to  determine  any  intra-day  variation.  These  studies 
were  also  repeated  on  different  days  to  determine  inter
variation. 
III. Accuracy 
To check accuracy of the method, recovery studies were carried 
out by addition of standard drug solution to pre
solution  at  three  different  levels  80,  100  and  120  %.  Mean 
percentage recovery was determined.
 IV. Limit of detection  
The detection limit of an individual analytical procedure is the 
lowest amount of analyte in a sample, which can be detected but 
not  necessarily  quantitated  as  an  exact  value.  Based  on  the 
standard deviation of the response and the slope, detection limit 
(LOD) may be expressed as: 
LOD =  
3.3
S
 
V. Limit of quantitation 
The quantitation limit of an individual analytical procedure is the 
lowest  amount  of  analyte  in  a  sample,  which  can  be 
quantitatively determined with suitable precision and accuracy. 
Based on the standard deviation of the response and the slope, 
The quantitation limit (LOQ) may be expressed as:
LOQ =  
10
S
Where,  
σ  =  the  standard  deviation  of  the  response  for  the  lowest 
concentration in the range  
S = the slope of the calibration curve.
 96 
 
day  variation.  These  studies 
were  also  repeated  on  different  days  to  determine  inter-day 
To check accuracy of the method, recovery studies were carried 
out by addition of standard drug solution to pre-analyzed sample 
solution  at  three  different  levels  80,  100  and  120  %.  Mean 
percentage recovery was determined. 
The detection limit of an individual analytical procedure is the 
lowest amount of analyte in a sample, which can be detected but 
essarily  quantitated  as  an  exact  value.  Based  on  the 
standard deviation of the response and the slope, detection limit 
3×σ 
S
 
The quantitation limit of an individual analytical procedure is the 
owest  amount  of  analyte  in  a  sample,  which  can  be 
quantitatively determined with suitable precision and accuracy. 
Based on the standard deviation of the response and the slope, 
The quantitation limit (LOQ) may be expressed as: 
10×σ 
S
 
  =  the  standard  deviation  of  the  response  for  the  lowest 
S = the slope of the calibration curve. Chawla et al. / Indian J. Pharm. Biol. Res., 2013; 1(4):95-101 
Original Research Article   97 
 
VI. Specificity 
The  specificity  of  the  method  was  ascertained  by  peak  purity 
profiling studies. Purity of the drug was ascertained by analyzing 
the spectrum at peak start, middle and at peak end. The peak 
purity  was  determined  on  Data  Ace  Chromatography  Work 
Station Software. 
VII. Robustness  
Robustness of the  method  was determined by carrying out by 
altering  mobile  phase  ratio,  chamber  saturation  time  and 
studying the effects on the area. 
VIII. Forced degradation studies  
Forced degradation studies of the bulk drug sample were also 
performed using the following conditions: acid hydrolysis (0.1N 
HCl), basic hydrolysis (0.1 N NaOH), heat (105°C for 96 hr), 
photolytic (UV and sunlight for 96 hr), oxidation (30% hydrogen 
peroxide)  and  reduction  (10%  sodium  metabisulphite)  peak 
purity  test  was  carried  out  for  Sparfloxacin  and  Ketorolac  by 
using UV detector.   
IX. Degradation under alkali catalyzed hydrolytic 
condition  
A solution of standard drug in 0.1N NaOH at a concentration of 
1000 µg/ml was refluxed for 8 hr and then 0.5 ml of the solution 
was  withdrawn  and  the  volume  was  made  up  to  10  ml  with 
methanol to get a concentration of 50 µg/ml of working solution. 
X. Degradation under acid catalyzed hydrolytic condition  
A solution of standard drug in 0.1N HCl, at a concentration of 
1000 µg/ml solution was refluxed for 8 hr and then 0.5 ml from 
the solution was withdrawn and the volume was made up to 10 
ml with methanol to get a concentration of 50 µg/ml of working 
solution. 
XI. Degradation under oxidative condition  
A solution of standard drug in 30% hydrogen peroxide solution 
at a concentration of 1000 µg/ml solution was refluxed for 8 hr 
and then 0.5 ml from the solution was withdrawn and the volume 
was made up to 10 ml with methanol to get 50 µg/ml working 
solution.  
XII. Degradation under dry heat  
Dry heat studies were performed by keeping drug sample in oven 
(105
°C) for a period of 96 hours. Samples were withdrawn after 
appropriate  time,  dissolved  in  methanol  and  diluted  to  get  10 
µg/ml working solution.  
XIII. Photo-degradation studies  
Photolytic studies were also carried out by exposure of drug to 
UV  light  for  a  period  of  96  hours.  Sample  was  weighed, 
dissolved and diluted to get 10 µg/ml working solution. 
 
3. Result and Discussion 
3.1 Optimization of the mobile phase  
Chromatographic separation studies were carried out 
on the working standard solution of sparfloxacin and 
ketorolac (100 µg/ml). Initially, trials were carried out 
using various solvents. After several trials, methanol: 
water (6:4 v/v) was chosen as the mobile phase, for 
HPLC, which resulted in good resolution. 
3.2 Summary of Degradation of Ketorolac 
 
Ketorolac  was  degraded  only  on  acidic  medium 
(Figure  9)  and  no  degradation  was  found  in  basic, 
oxidation,  reduction,  thermal,  and  photolytic 
condition. 
 
Table 1: Robustness summary 
 
S. 
No. 
Parameters  Variation                 % RSD 
Sparfloxacin  Ketorolac 
1.  Flow rate  ±2ml/min  0.703  0.537 
2.  pH  ±2  1.054  0.466 
3.  Wavelength  ±5nm  0.978  1.083 
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Table 2: Summary of validation study 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Summary of Degradation of Sparfloxacin 
 
S. 
No.  
Condition   Duration  Remark  
1.   Acid Hydrolysis 
(0.1N HCl) 
8 hr  Some degradation was found, but main peak was homogeneous.  
2.   Base hydrolysis 
(0.1N NaOH) 
8 hr  No degradation was found, main peak was homogeneous.  
3.   Oxidation 
(30% H2O2) 
8 hr  Degradation was observed, but main peak was homogeneous.  
4.   Reduction 
(10% Na2S2O5) 
8 hr  Degradation was observed, but main peak was homogeneous  
5.   Thermal 
(105
°C) 
12hr  No degradation was found.  
6.   Sunlight  6 hr  No degradation was found.  
 
Table 4: Summary of Degradation of Ketorolac 
 
S.N.  Parameter  Sparfloxacin  Ketorolac 
1.  Linearity  Y=82.91X+41.72,  R
2=0.999  Y=121.2X+39.89, R
2=0.999 
2.  Range  5-80 µg/ml  5-80 µg/ml 
 
3. 
Precision 
Intra Day 
   Inter Day 
%RSD  %RSD 
0.281%  0.279% 
0.135%  0.271% 
4.  Accuracy 
   A. 80% 
B. 100% 
C. 120% 
% Recovery  % Recovery 
99.76%  100.55% 
98.70%  98.69% 
99.89%  99.82% 
5.  LOD  0.307 µg/ml  0.238 µg/ml 
6.  LOQ  0.931 µg/ml  0.722 µg/ml 
7.  Specificity  Specific  Specific 
8.  Robustness  Robust  Robust 
S.N.   Condition   Time   Remark  
1.   Acid Hydrolysis 
      (0.1N HCl)  
8 hr   Degradation was found.  
2.   Base hydrolysis 
   (0.1 N NaOH)  
8 hr  No degradation was found.  
3.   Oxidation 
(30% H2O2)  
8 hr  No degradation was found.  
4.   Reduction 
(10% Na2S2O5)  
8 hr  Degradation was not found. 
5.   Thermal 
(105
0C) 
12hr  No degradation was found.  
6.   Sunlight   6 hr  No degradation was found.  Chawla et al. / Indian J. Pharm. Biol. Res., 2013; 1(4):95-101 
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Table 5: Stability and Interaction study of mixed std. drug sample 
 
 
 
 
 
 
 
 
 
Figure 2: Chromatogram of Sparfloxacin and Ketorolac 
 
Figure 3: Sparfloxacin degradation in 0.1N HCl 
 
Figure 4: Sparfloxacin degradation in 0.1N NaOH 
S. 
No.  
Drug   0
th day   3
rdday   5
th day  7
th day  10
th day 
1.   Sparfloxacin   430.524  431.793  432.894   430.256  430.0853 
2.   Ketorolac   622.271  623.327  623.779  621.442  622.1433 Chawla et al. / Indian J. Pharm. Biol. Res., 2013; 1(4):95-101 
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Figure 5: Sparfloxacin degradation in 30% H2O2 
 
Figure 6:Sparfloxacin degradation in 10% Na2S2O5 
 
Figure 7:Sparfloxacin degradation after exposing to heat 
 
Figure 8: Sparfloxacin degradation after exposing to UV light 
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Figure 9: Ketorolac degradation in 0.1NHCl 
In above table the area of Sparfloxacin and Ketorolac at different 
days are represented. No significant  variation in area was found  
for both drugs, and no other peak was found. Thus, there was no 
interaction and the standard drug sample was stable till 10
th day. 
 
4.Conclusion  
A new method for the simultaneous estimation of ketorolac and 
sparfloxacin in bulk material, pharmaceutical dosage formulation 
has been developed for the first time. The proposed RP-HPLC 
method is simple, rapid, isocratic, specific, accurate and precise. 
Hence, it can be recommended for the routine quality control. 
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